Wellness Wire Kansas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Wire Kansas.

Press releases published on October 9, 2026

9 hours ago

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

Indeterminate GlobeNewswire

9 hours ago

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Indeterminate GlobeNewswire

9 hours ago

Trillium Dental’s Dr. Mark Northcott Reveals Which Halloween Treats Damage Kids’ Teeth and Which Are Surprisingly Safe

Indeterminate GlobeNewswire

9 hours ago

Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference 

Indeterminate GlobeNewswire

10 hours ago

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

Indeterminate GlobeNewswire

10 hours ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

10 hours ago

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

Indeterminate GlobeNewswire

11 hours ago

T·Time Launches Cash-Pay Compounded GLP-1 and GIP Injections With Flat Pricing

Indeterminate GlobeNewswire

12 hours ago

A promising new chapter for PI3Kδ inhibition: Nature Communications publications reveal novel mechanism behind iOnctura's roginolisib

Indeterminate GlobeNewswire

12 hours ago

Caregivers Need a Break: New No-Cost Day Program Opens in East St. Louis

Indeterminate GlobeNewswire

13 hours ago

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Indeterminate GlobeNewswire

16 hours ago

TherapiAI Showcases Agentic AI Platform for Biopharma at BioJapan 2026

Indeterminate GlobeNewswire

16 hours ago

セラピAI、バイオジャパン2026でバイオ医薬品向けエージェント型AIプラットフォームを披露

Indeterminate GlobeNewswire

Oct. 9, 2026

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

Indeterminate GlobeNewswire

Oct. 9, 2026

TRexBio Announces Pricing of Initial Public Offering

Indeterminate GlobeNewswire